Stocks › INCY
INCYTE CORP
INCY·Nasdaq·
United States·USD
United States·USD$112.73
-1.40 (-1.23%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
INCY
INCYTE CORP · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
INCYS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of INCY by members of U.S. Congress · 39 on record · 3 in the last 12 months
Whale Activity
Position changes in INCY reported for 2026-06-30 by 18 tracked institutional filers
- Increased5
- New1
- Held0
- Decreased3
- Closed1
- No prior filing8
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 18.0M | $2.04B | decreased |
| DODGE & COX | 12.0M | $1.36B | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 11.0M | $1.25B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7.8M | $883.2M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 3.5M | $398.1M | decreased |
| TWO SIGMA INVESTMENTS, LP | 2.0M | $227.1M | increased |
| Illinois Municipal Retirement Fund | 260.3K | $29.5M | — |
| ASHFORD CAPITAL MANAGEMENT INC | 182.2K | $20.7M | — |
| Bridgewater Associates, LP | 168.3K | $19.1M | increased |
| CITADEL ADVISORS LLC | 143.5K | $16.3M | increased |
| MILLENNIUM MANAGEMENT LLC | 82.8K | $9.4M | decreased |
| L2 Asset Management, LLC | 61.8K | $7.0M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by INCY insiders, by quarter · Form 4
Recent Insider Transactions
2,653 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| CAGNONI PABLO JPresident, Global Head of R&D | Sale | −9,233 | $120.50 | $1.1M | Sep 15, 2026 | Form 4 ↗ |
| CAGNONI PABLO JPresident, Global Head of R&D | Sale | −14.0K | $120.49 | $1.7M | Sep 15, 2026 | Form 4 ↗ |
| CAGNONI PABLO JPresident, Global Head of R&D | Sale | −10.8K | $125.56 | $1.4M | Aug 19, 2026 | Form 4 ↗ |
| CAGNONI PABLO JPresident, Global Head of R&D | Sale | −10.8K | $120.04 | $1.3M | Aug 12, 2026 | Form 4 ↗ |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | −2,207 | $123.99 | $274K | Aug 5, 2026 | Form 4 ↗ |
| CAGNONI PABLO JPresident, Global Head of R&D | Sale | −10.6K | $122.69 | $1.3M | Aug 5, 2026 | Form 4 ↗ |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | −6,055 | $120.43 | $729K | Aug 3, 2026 | Form 4 ↗ |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | −85 | $122.19 | $10K | Jul 31, 2026 | Form 4 ↗ |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | −6,171 | $119.43 | $737K | Jul 31, 2026 | Form 4 ↗ |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | −5,332 | $119.42 | $637K | Jul 31, 2026 | Form 4 ↗ |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | −4,695 | $119.39 | $561K | Jul 31, 2026 | Form 4 ↗ |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | −326 | $121.69 | $40K | Jul 31, 2026 | Form 4 ↗ |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | −2,864 | $119.40 | $342K | Jul 31, 2026 | Form 4 ↗ |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | −2,293 | $119.41 | $274K | Jul 31, 2026 | Form 4 ↗ |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | −2,187 | $119.47 | $261K | Jul 31, 2026 | Form 4 ↗ |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | −1,643 | $119.51 | $196K | Jul 31, 2026 | Form 4 ↗ |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | −1,642 | $119.38 | $196K | Jul 31, 2026 | Form 4 ↗ |
| Mayes Patrick AEVP & Chief Scientific Officer | Sale | −14.7K | $119.46 | $1.8M | Jul 31, 2026 | Form 4 ↗ |
| CAGNONI PABLO JPresident, Global Head of R&D | Sale | −15.9K | $119.70 | $1.9M | Jul 31, 2026 | Form 4 ↗ |
| Issa Mohamed KhairieEVP, Head of U.S. Commercial | Sale | −1,093 | $115.01 | $126K | Jul 16, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding INCY · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Dodge & Cox Stock Fund Dodge & Cox Funds | 8.0M | $901.6M | 0.76% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 5.4M | $611.1M | 0.03% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 4.3M | $492.8M | 0.03% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.9M | $441.5M | 0.23% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 2.4M | $285.2M | 0.75% | Jul 31, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 2.3M | $261.8M | 0.03% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 2.2M | $254.6M | 0.54% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 2.0M | $228.9M | 0.03% | Jun 30, 2026 |
| Invesco S&P 500 Equal Weight ETF Invesco Exchange-Traded Fund Trust | 1.8M | $211.3M | 0.22% | Jul 31, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 2.1M | $207.0M | 0.02% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list INCY's shares (CUSIP 45337C102), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Dodge & CoxSCHEDULE 13G/A · passive (13G) · 12.3M shares6.2%
May 14, 2026 · ↗ - FBB AssociatesSCHEDULE 13D/A · activist (13D) · 33.4K shares0.0%
May 11, 2026 · ↗ - FBB3 LLCSCHEDULE 13D/A · activist (13D) · 31.1K shares0.0%
May 11, 2026 · ↗ - FBB2, LLCSCHEDULE 13D/A · activist (13D) · 14.8K shares0.0%
May 11, 2026 · ↗ - Felix J. BakerSCHEDULE 13D/A · activist (13D) · 31.2M shares15.6%
May 11, 2026 · ↗ - Julian C. BakerSCHEDULE 13D/A · activist (13D) · 31.2M shares15.6%
May 11, 2026 · ↗ - Baker Bros. Advisors (GP) LLCSCHEDULE 13D/A · activist (13D) · 30.9M shares15.4%
May 11, 2026 · ↗ - Baker Bros. Advisors LPSCHEDULE 13D/A · activist (13D) · 30.9M shares15.4%
May 11, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming incyte as client
- W STRATEGIES, LLCINCYTE CORPORATION · 2026 Q2 · MMM$60K
Filing ↗ - AVENUE SOLUTIONSINCYTE CORPORATION · 2026 Q2 · HCR, MMM$60K
Filing ↗ - INCYTE CORPORATIONINCYTE CORPORATION · 2026 Q2 · MMM$750K
Filing ↗ - TIBER CREEK GROUPINCYTE CORPORATION · 2026 Q2 · MMM, HCR$80K
Filing ↗ - CHECKMATE GOVERNMENT RELATIONSINCYTE CORPORATION · 2026 Q2 · MMM$110K
Filing ↗
Government Contracts
Federal awards to INCYTE CORP · USAspending
No federal contract awards found for INCYTE CORP.
U.S. Patents
Recent USPTO applications naming INCYTE CORP
No USPTO patent applications found for INCYTE CORP.
Annual Financials
From INCY's 10-K filings · XBRL
No annual XBRL figures on record for INCY. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 2-for-1Stock splitSep 1, 2000
- 2-for-1Stock splitNov 10, 1997
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 8.01Other eventsAug 31, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 28, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJul 6, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsJun 22, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 9, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsJun 8, 2026
EDGAR ↗
About INCYTE CORP
From SEC EDGAR company records
Industry (SIC 8731)Services-Commercial Physical & Biological Research
SectorIndustrials
HeadquartersWILMINGTON, DE
IncorporatedDE
SEC CIK0000879169 ↗
Former namesINCYTE INC, INCYTE GENOMICS INC, INCYTE PHARMACEUTICALS INC